Danaparoid: An antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans

Journal of Internal Medicine

Volumn 242, Issue 2, 1997, Pages 125-129

  Van Barlingen, Harrold H J J ^a   Van Beek, A ^a   Erkelens, D W ^a   De Bruin, T W A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Danaparoid; Heparin; Lipoprotein lipase; Triglyceride

Indexed keywords

DANAPAROID; HEPARIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; ANTICOAGULATION; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; LIPOLYSIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030854802     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1997.00157.x     Document Type: Article

References (23)

1. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-83.
2. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500.
3. Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Meisl T, et al. Influence of various heparin preparations on lipoproteins in hemodialysis patients: A multicentre study. Thromb Haemost 1995; 74: 1025-8.
4. Ofusu FA, Buchanan MR, Anavari N, Smith LM, Blajchman MA. Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulphate, and Dermatan Sulphate. Ann N Y Acad Sci 1989; 556: 123-31.
5. Chevreuil O, Hultin M, Ostergaard P, Olivecrona T. Depletion of lipoprotein lipase after heparin administration. Arterioscler Thromb 1993; 13: 1391-6.
6. Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, et al. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994; 35: 229-38.
7. Chan MK, Persaud J, Varghese Z, Moorehead JF. Pathogenic roles of postheparin lipase in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812-18.
8. Eckel RH. Lipoprotein Lipase: a multifunctional enzyme relevant to common metabolic disease. N Engl J Med 1989; 320: 1060-68.
9. Kawamura M, Shimano H, Gotoda T, Harada K, Shimada M, Ohsuga J, et al. Overexpression of human lipoprotein lipase enhances uptake of lipoproteins containing apolipoprotein B100 in transacted cells. Arterioscler Thromb 1994; 14: 235-42.
10. Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein Lipase and hepatic lipase. Curr Opin Lipidol 1993; 4: 187-96.
11. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoproteinrelated protein. Proc Natl Acad Sci USA 1991; 88: 8342-6.
12. Mulder M, Lombardi P, Jansen H, van Berkel TJC, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low-density and very low density lipoproteins that are bound to heparan sulphate proteoglycans via lipoprotein lipase. J Biol Chem 1993; 268: 9369-75.
13. Williams KJ, Petrie KA, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro. J Clin Invest 1991; 88: 1300-6.
14. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS & Valle D. eds. The Metabolic Basis of Inherited Disease. New York, USA: McGraw Hill, 1989: 1165-79.
15. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trail. Ann Intern Med 1995; 123: 1-9.
16. van Barlingen HHJJ, de Jong H, Erkelens DW, de Bruin TWA. Lipoprotein lipase enhanced binding of human triglyceriderich lipoproteins to heparan sulphate: modulation by apolipoprotein E and apolipoprotein C J Lipid Res 1996; 37: 754-63.
17. van Barlingen HHJJ, Kock LAW, de Man HAF, Erkelens DW, de Bruin TWA. In vitro lipolysis of human VLDL: effect of different VLDL composition in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Atherosclerosis 1996; 121: 75-84.
18. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978; 87: 206-10.
19. Huttunen JK, Enholm C, Kinnunen PKJ, Nikkilä EA. An immunochemical method for the selective measurment of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975; 63: 335-47.
20. Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in haemodialysis: longterm effects on postheparin lipases. Scand J Clin Lab Invest 1994; 54: 515-21.
21. Olivecrona T, Bengtsson-Olivecrona G, Ostergaard P, Liu G, Chevreuil O, Hultin M. New aspects on heparin and lipoprotein metabolism. Haemostasis 1993; 23: 150-160.
22. Chevreuil O, Hultin M, Ostergaard P, Olivecrona T. Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. Arterioscler Thromb 1993; 13: 1397-1403.
23. Kronenbcrg F, Köning P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clinical Nephrology 1995; 43: 399-404.